WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...

Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped ...

Aviceda Therapeutics’ eye disease drug will advance to Phase III, despite it failing to meet the primary endpoint in a Phase IIb trial. In the SIGLEC study (NCT05839041), AVD-104 showed no statistical ...

A new phase shifter does not need clean-room facilities for fabrication, so is inexpensive to manufacture. The liquid-metal enabled phase shifting elements have a 'passive' nature, unlike the 'active' ...

Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...

Based on successful Phase 3 trial results, that approval is expected to come over the next few months. This new data, announced in a press release from pharma company Eli Lilly and yet to be ...

ZHENJIANG, China--(BUSINESS WIRE)--At 10:16 on January 17, State Grid Zhenjiang Power Supply Company successfully resolved a phase loss fault between Poles 17 and 18 on the 10 kV Antou 292 line of the ...

A new publication from Opto-Electronic Advances, 10.29026/oea.2023.220085 discuss broadband low-loss all-optical phase modulator using gas-filled hollow-core fiber. Optical phase modulators are key ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.

Researchers have clarified the mechanisms by which energy loss is locally maximized at a certain rotational speed in gas-liquid two-phase flows driven by rotors, providing fundamental insights for ...